Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 9 (1) , 92-99
- https://doi.org/10.1111/j.1538-7836.2010.04100.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging StudyBlood, 2008
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging studyJournal of Thrombosis and Haemostasis, 2008
- Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapyJournal of Thrombosis and Haemostasis, 2008
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2008
- Extended Prophylaxis of Venous Thromboembolism with IdraparinuxNew England Journal of Medicine, 2007
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)Circulation, 2007
- Treatment of Deep-Vein ThrombosisNew England Journal of Medicine, 2004
- Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous ThrombosisAnnals of Internal Medicine, 2004
- Home Treatment of Deep Vein ThrombosisPathophysiology of Haemostasis and Thrombosis, 2002